Enliven Therapeutics, Inc. (ELVN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Enliven Therapeutics, Inc. (ELVN:NASDAQ), powered by AI.

Current Price
$46.13
Sector
Healthcare
What is the Enliven Therapeutics, Inc. stock price forecast?

Enliven Therapeutics, Inc. is currently trading at $46.13. View real-time AI analysis on Alpha Lenz.

What is Enliven Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Enliven Therapeutics, Inc. on Alpha Lenz.

What is Enliven Therapeutics, Inc.'s P/E ratio?

View Enliven Therapeutics, Inc.'s valuation metrics on Alpha Lenz.

Enliven Therapeutics, Inc.

NASDAQ · ELVN
$46.13+5.77(+14.30%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Enliven Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Enliven Therapeutics, Inc.'s ROE is -27.0%. Explore profitability and growth together.

Ask for details

Company Overview

Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases. The primary focus of the company lies in advancing the field of precision medicine, which aims to tailor medical treatment to the individual characteristics of each patient, enhancing treatment efficacy and minimizing side effects. Enliven Therapeutics Inc. is actively engaged in researching and developing targeted therapies that address unmet medical needs across various therapeutic areas, particularly concentrating on genetic disorders and oncology. By leveraging cutting-edge technology platforms and innovative research methodologies, Enliven Therapeutics seeks to offer groundbreaking treatments that have a significant impact on patient care and outcomes. The company plays a vital role in the pharmaceutical and healthcare sectors, contributing to the rapid evolution of personalized healthcare solutions. In the financial market, Enliven Therapeutics represents an integral component of the biotechnology sector, often garnering interest from investors focused on emerging biotech innovations and their potential to transform traditional medical practices.

CEOMr. Samuel S. Kintz M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees63

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
63Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-25.86%ROA
-26.95%ROE
-29.84%ROIC

Financial Health

$98.90MCash & Cash Equivalents
$-82.33MNet Debt
3.60%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Enliven Therapeutics, Inc. (ticker: ELVN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 63 employees.

The current price is $46.13 with a P/E ratio of -x and P/B of -x.

ROE is -26.95%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Enliven Therapeutics, Inc. (ELVN) Stock Forecast 2026 $46.13 — Price, Financials & Analyst Targets | Alpha Lenz